New eye drug trial aims to Fine-Tune treatment for blinding disease
NCT ID NCT07367282
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study tests the drug faricimab (Vabysmo) in 64 adults with wet age-related macular degeneration, a leading cause of vision loss. Participants receive eye injections every 4 weeks for 4 doses, then the schedule is adjusted based on how the eye responds. The goal is to see if the drug controls the disease and to measure certain eye fluid markers that may predict treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.